Hamlet BioPharma AB publ (XSAT:HAMLET B) Other Current Receivables: kr1.72 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:HAMLET B Hamlet BioPharma AB publ XSAT:HAMLET B
31 GF Score
Price kr5.30
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ Other Current Receivables?

Hamlet BioPharma AB publ XSAT:HAMLET B -2.57% 31 Other Current Receivables is kr1.72 Mil as of Jun. 2026. GuruFocus rates XSAT:HAMLET B with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Hamlet BioPharma AB publ's Other Current Receivables for the quarter that ended in Jun. 2026 was kr1.72 Mil.

Hamlet BioPharma AB publ's quarterly Other Current Receivables increased from Dec. 2025 (kr3.04 Mil) to Mar. 2026 (kr3.35 Mil) but then stayed the same from Mar. 2026 (kr3.35 Mil) to Jun. 2026 (kr1.72 Mil).

Hamlet BioPharma AB publ's annual Other Current Receivables declined from Jun. 2024 (kr4.20 Mil) to Jun. 2025 (kr2.00 Mil) and declined from Jun. 2025 (kr2.00 Mil) to Jun. 2026 (kr1.72 Mil).

Hamlet BioPharma AB publ Other Current Receivables Related Terms

Hamlet BioPharma AB publ Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Hamlet BioPharma AB publ's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ Other Current Receivables Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.12 0.62 4.20 2.00 1.72

Hamlet BioPharma AB publ Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.60 3.04 3.35 1.72
XSAT:HAMLET B
31GF Score
Hamlet BioPharma AB publ XSAT:HAMLET B
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr1.72 Mil mean?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a Other Current Receivables of kr1.72 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Hamlet BioPharma AB publ and its competitors.
Is Hamlet BioPharma AB publ's Other Current Receivables too high?
Hamlet BioPharma AB publ's current Other Current Receivables is kr1.72 Mil. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's Other Current Receivables compare to VRTX and REGN?
Hamlet BioPharma AB publ's Other Current Receivables of kr1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Hamlet BioPharma AB publ and its competitors. Hamlet BioPharma AB publ's current Other Current Receivables is kr1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (XSAT:HAMLET B) has a current Other Current Receivables of kr1.72 Mil. The current Other Current Receivables is kr1.72 Mil. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Hamlet BioPharma AB publ (XSAT:HAMLET B), the current Other Current Receivables is kr1.72 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges 7ZT:Germany
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for XSAT:HAMLET B

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.30
Price